Shows
BioTalk UnzippedFail Fast, Learn Faster: Drug Development in Rare Disease with Dr. Binodh DeSilvaIn this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Binodh DeSilva, Senior Vice President of Bioanalysis at Ultragenyx Pharmaceutical, to explore the science and soul behind rare-disease drug development.From her early days studying electrochemistry at the University of Kansas to leading cutting-edge bioanalytical programs at Ultragenyx, Dr. DeSilva shares how curiosity and community shaped her four-decade career. She discusses the profound responsibility of working with limited, often irreplaceable patient samples with care.A special thanks to AAPS (https://www.aaps.org/) for their help and support of...
2025-10-2331 min
BiotalkEpisode 31: Asia’s 2025 Q3 Report: Global Trends in Biopharma TransactionsDuring Episode 31 of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores Asia-Pacific biotech momentum across China, Japan, and Korea, as featured in our 2025 Q3 Report: Global Trends in Biopharma Transactions Report.
China: Led globally in licensing ($34.2B, 48% share), with venture financing up nearly 4x. Investor confidence rose alongside strong public market gains and creative deal structures.
Japan: Shifted toward early-stage, non-core areas like dermatology and metabolic disease. Licensing values fell, but venture funding spiked 300% as the Nikkei hit record highs.
Korea: Normalized after Q2 strength; modest licensing and market gains amid continued caution.
...
2025-10-2004 minBiotalkBiotalk Episode 30: 2025 Q3 Report: Global Trends in Biopharma TransactionsDuring Episode 30 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q3 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends.
Market Overview: Q3 signaled a cautious biotech recovery. Valuations rebounded, the XBI topped 100 for the first time since 2022, and the number of companies trading below cash hit multi-year lows. Investor sentiment shifted from survival to selective growth amid improving macro stability and risk tolerance.
Strategic Transactions: Licensing held steady with renewed interest in early-stage programs and back-loaded structures (upfronts
2025-10-2013 minBioTalk UnzippedUnlocking Antibody Development with AI with Dr. Pin-Kuang LaiIn this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe interview Asst. Professor Pin-Kuang Lai from Stevens Institute of Technology about his keynote speech at AAPS NBC 2025 and the intersection of AI and molecular engineering, particularly in predicting the viscosity of monoclonal antibodies. They discuss the challenges of high concentration formulations, the importance of AI validation, and the future of formulation development. Lai shares insights from his international research journey and collaborations with pharmaceutical companies, as well as opportunities for students interested in this field.00:00 Preview & Intro01:58 Deep Viscosity and AI in...
2025-09-1217 minBiotalkEpisode 29: Asia’s 2025 Q2 Report: Global Trends in Biopharma TransactionsDuring the Asia-focused Episode 29 of Biotalk, Geoff shares insights into key trends and developments shaping the biotech landscapes in Japan, China, Korea, Australia, and the broader Asia-Pacific region, as featured in our 2025 Q2 Report: Global Trends in Biopharma Transactions Report.
Japan’s biotech stocks outperformed broader indices, boosted by regulatory reforms and Shionogi’s $1.1B acquisition of Japan Tobacco’s pharma units. Licensing slowed, while early-stage financings focused on preclinical firms.
China’s biotech market surged with four HKEX IPOs raising $1.5B. Venture funding fell as risk aversion grew, but strategic licensing stayed strong at $24.4B, shift...
2025-07-2307 minBiotalkBiotalk Episode 28: 2025 Q2 Report: Global Trends in Biopharma TransactionsDuring Episode 28 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q2 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends.
Market Overview: Biotech remained under pressure in Q2, with valuations still below historical norms. Ongoing macro headwinds—tariffs, high rates, and FDA turnover—kept investor sentiment cautious and risk appetite low.
M&A & Licensing: Licensing rose 20% in value, focused on late-stage immunology assets. China and Europe drove activity, while U.S. firms dominated M&A, accounting for 80% of deal value. Public takeout premiums rebounded sharply.
Capit...
2025-07-2317 minBioTalk UnzippedThe Science and Hope of Brain Cancer with Dr. Robert Thorne, Denali TherapeuticsIn this powerful episode (#35) of BioTalk Unzipped, recorded live at the AAPS NBC conference in Boston, Gregory Austin engages in a deep conversation with a leading Neuroscientist, Dr. Robert Thorne, Denali Fellow at Denali Therapeutics, for an intimate and scientific deep dive into the evolving world of brain cancer treatment and CNS drug delivery. Both Gregory and Dr. Thorne share personal stories of losing family members to brain metastases, weaving in the emotional 'why' behind their professional paths.Dr. Thorne highlights the complexities of the blood-brain barrier, the heterogeneity of brain metastases, and cutting-edge delivery technologies—including fo...
2025-07-0322 minBioTalk UnzippedInside AAPS NBC with AAPS President Dr. Russ WeinerIn this special episode (#34) of BioTalk Unzipped, recorded live at the AAPS NBC conference in Boston, Gregory Austin and Dr. Chad Briscoe sit down with AAPS President Dr. Russ Weiner for an unfiltered look inside AAPS NBC, at the state of rare disease research, the evolution of therapeutic modalities, and the human stories that drive scientific innovation.From navigating the emotional weight of personal loss to watching his son experience the field firsthand, Russ shares not only his scientific insights but the heart behind his leadership. The conversation spans topics like the rising promise of AI diagnostics...
2025-06-0828 minBioTalk UnzippedBuilding Successful Life Science Companies with Katrina RogersIn this powerful episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Katrina Rogers, a 25-year life sciences veteran, biotech equity advocate, and founder of Evergreen Bioscience Innovation and Katrina Rogers Consulting. Katrina shares her compelling journey from Pfizer to pioneering innovation ecosystems and mentoring underrepresented biotech founders. They unpack the role of board governance, the funding gap for female founders, and how "showing your science" is critical for regulatory success. Katrina also warns of dangerous gaps in understanding between regulators and innovators and why we must protect our basic science infrastructure. If you've ever...
2025-05-1259 minBiotalkEpisode 27: Inside the Biopharma Market: 2025 Outlook & Emerging TrendsDuring Episode 27 of Biotalk, Geoff Meyerson, CEO of Locust Walk, steps back to examine the macro forces shaping the biopharma landscape. After holding a bearish outlook since 2021, Geoff explains why he’s finally shifting his stance and what could signal a true turnaround for biotech.
He unpacks the “big three” market headwinds—regulatory hurdles from the IRA, FTC deal scrutiny, and high interest rates—and outlines how recent shifts, including rate cuts, new FTC leadership, and potential IRA reform, could spark renewed momentum, especially in M&A and rare diseases. Geoff also highlights previously underappreciated risks like HHS cuts a...
2025-05-0707 minBiotalkEpisode 26: Asia’s 2025 Q1 Report: Global Trends in Biopharma TransactionsDuring the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea, as featured in our 2025 Q1 Report: Global Trends in Biopharma Transactions Report.
Japan saw modest market recovery, a $3.3B buyout of Mitsubishi Tanabe, and lighter licensing activity. Early-stage financings picked up as investors re-engaged.
China shifted from IPO optimism to global deal-making as markets cooled. Notable trends included strong out-licensing ($17.6B), AstraZeneca’s $2.5B investment, and Ascentage’s NASDAQ debut backed by Takeda. Venture activity rebounded, driven by insider-led late-stage rounds.
Korea drew attenti...
2025-04-1610 minBiotalkBiotalk Episode 25: 2025 Q1 Report: Global Trends in Biopharma TransactionsDuring Episode 25 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q1 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends.
Market Overview: The XBI fell 14% YoY, underperforming the NBI. Biotech weakness stemmed from tariff fears, FDA turnover, and HHS layoffs—pressuring small caps.
Capital Markets: Capital raised dropped 33% from Q4. IPOs briefly reopened—large caps gained, small caps declined. Follow-ons fell 60%. PIPEs were weak, except Immunovant’s $450M.
Venture: Slight dip from Q4 but ahead of all 2023 quarters. Late-stage rounds led, with 11 mega-rounds (Eikon $351M, Kardig...
2025-04-1613 minBioTalk UnzippedNavigating Challenges in Drug Discovery with Dr. Alfred BotchwayIn this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Alfred Botchway, CEO of Attentive Science, to discuss his journey in biomedical science and the groundbreaking work being done at the intersection of AI, non-clinical safety, and drug discovery. Dr. Botchway shares his insights on the role of AI in refining toxicology studies, how stress impacts human health, and his experience founding companies like Xenometrics and Attentive Science.The conversation dives deep into the complexities of Good Laboratory Practices (GLP), the importance of regulatory standards, and the exciting research happening in...
2025-04-0751 min
BioTalk Unzipped2024 Year In Review: BioTalk UnzippedIn this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe reflect on their journey over the past year, discussing key themes and insights gained from their guests. They explore the humanistic approach to healthcare, the impact of AI in drug development, common threads among successful individuals, personal growth through conversations, and the importance of leadership and mentorship in the industry. The episode concludes with exciting plans for future series focused on drug development and global healthcare innovations.Thanks to CREO Consulting for hosting this episode!https://creoconsulting.com/
2025-03-1741 min
BioTalk UnzippedWomen in Pharmaceutical Sciences and their Allies with Dr. Ines Santos and Dr. Julie SableIn this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe welcome Dr. Ines Santos and Dr. Julia Sable to discuss their experiences and contributions in the pharmaceutical sciences, particularly focusing on women's roles in the field. The conversation covers their personal journeys into science, the importance of STEAMpark.org in education, exciting projects they've worked on, challenges in CMC for cell and gene therapies, innovations in chiral bioanalysis, and recent industry developments. The panel emphasizes the significance of collaboration and mentorship in advancing medical progress. This conversation delves into the evolving landscape of cancer treatment, particularly the...
2025-03-031h 11
BioTalk UnzippedAre AI Doctors coming soon? A Discussion about AI in Medical Devices. - with Dr. Alex FriedmanIn this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe welcome Dr. Alex Friedman, a seasoned expert in regulatory affairs for medical devices and AI as Software as a Medical Device. Chapters02:26 Introduction to BioTalk Unzipped03:40 Charity Spotlight: Americares05:01 Dr. Alex Friedman's Career Journey11:52 The Regulatory Landscape of Medical Device Classifications18:52 Regulatory Gameshow!: Classifying Medical Devices22:28 AI Enabled Software as a Medical Device: An...
2025-02-031h 10BiotalkBiotalk Episode 24: Asia's 2024 Year-In-ReviewDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores the evolving biotech landscapes in Japan and China, highlighting key trends and developments shaping the region as featured in our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff leverages extensive conversations with strategics and investors worldwide to provide insights into global biotech deal-making. Key topics include:Japan’s Recovery in 2024: A rebound in licensing activity reached $2.1B in Q4, driven by preclinical and small molecule deals. Venture financing grew 20%, with Series C and D rounds leading the charge....
2025-01-2812 minBiotalkBiotalk Episode 23: 2024 Year-In-Review Report: Global Trends in Biopharma TransactionsDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff dives into the insights from the comprehensive report and offers a forward-looking perspective on what 2025 may bring for the biotech industry. Key topics include:Capital Markets Performance: The XBI ended flat, down 0.2%, underperforming the S&P 500’s 24% gain. However, 2024 saw a 156% increase in capital raised compared to 2022, with IPO and follow-on financings improving in Q4.Venture Financing Trends: Q4 venture financing remained stable at ~$4B across 43 deals, wi...
2025-01-2113 min
BioTalk UnzippedCollaborating for Innovation: Biopharma Success with Dr. Nathan TeuscherIn this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe continue their conversation with Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. They discuss the challenges and opportunities presented by new technologies, particularly in drug development and patient engagement. The conversation highlights the evolution of pharmaceuticals, and the potential of virtual clinical trials. In this conversation, Nathan Teuscher discusses the importance of optimizing drug dosages in oncology, the challenges faced in cell therapy, and the complexities of treating immunocompromised patients. He emphasizes the need for collaboration in the scientific community and shares his perspective...
2025-01-2031 min
BioTalk UnzippedThe Future of Pharmacometrics with Dr. Nathan TeuscherIn this episode of BioTalk Unzipped, hosts Gregory Austin and Chad Briscoe welcome Dr. Nathan Teuscher, a seasoned expert in clinical pharmacology and pharmacometrics. The conversation explores Nathan's career journey, the innovative charity Light the World, and the transformative role of AI in drug development. They discuss the challenges and opportunities presented by AI, particularly in automating data analysis and rethinking traditional reporting methods in the pharmaceutical industry. The episode emphasizes the potential for small companies to leverage cloud-based tools and APIs to enhance efficiency and drive innovation in drug development. In this conversation, the speakers explore the intersection...
2025-01-0633 min
Clinical Pharmacology Podcast with Nathan TeuscherCollaboration with BioTalk Unzipped (Ep. 40)In this episode I share a couple short clips from my conversation with Chad Briscoe and Greg Austin from BioTalk Unzipped (www.biotalkunzipped.com). We chat about a variety of topics including artificial intelligence and challenges with cell therapy development. You can hear the entire conversation on the BioTalk Unizipped podcast or YouTube channel in January. For now, enjoy these clips from the upcoming show!
Links discussed in the show:
BioTalk Unzipped main page
BioTalk Unzipped YouTube channel
You can connect with me on LinkedIn and send me a message
Send me a message
Sign up for my new
2024-12-3013 min
BioTalk UnzippedInsights from AAPS PharmSci 360 Live with Dr. Mark ArnoldIn this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients. Chapters00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 36003:45 Samaritan's Purse C...
2024-12-3029 min
BioTalk UnzippedDigital Twins: The Future of Drug Discovery with Dr. Tomáš HelikarBioTalk Unzipped, hosts Gregory Austin and Chad Briscoe engage with Dr. Tomas Helikar in an exciting discussion on the future of AI, digital twins, and personalized medicine. From mathematical models and immune system simulations to groundbreaking collaborations with the Department of Defense, this episode uncovers how digital twins have the potential to transform drug discovery and clinical trials. Don’t miss insights on the ethical challenges of data privacy, the promise of animal digital twins, and the latest AI breakthroughs like MIT’s Sparrow algorithm!
Chapters
01:00 How the mathematical models work. Normalization and Scaling in C...
2024-12-1637 minBiotalkBiotalk Episode 22: A Conversation with Sudhir Agrawal of ARNAY SciencesOn this episode of Biotalk, Geoff Meyerson, CEO and Co-founder of Locust Walk, speaks with Sudhir Agrawal, Founder and President of ARNAY Sciences and a pioneer in RNA therapeutics. Sudhir’s extensive career spans over three decades, during which he has made groundbreaking contributions to the field, including developing gapmer antisense technology, immune modulation approaches, and, in recent years, designing cyclic structures of DNA and RNA for therapeutic applications.In their conversation, Sudhir recounts his journey from his early days in nucleic acid research to becoming a leading innovator in RNA th...
2024-12-1029 min
BioTalk UnzippedTransforming Immunology: The Promise of Digital Twins with Dr. Tomáš HelikarDr. Tomas Helikar, a leading researcher in bioinformatics and systems biology, delves into groundbreaking work on developing a personalized immune digital twin, which aims to revolutionize the understanding and treatment of immune-related diseases.
Chapters
00:00 Introduction to BioTalk Unzipped
01:50 Meet Dr. Tomas Helikar
04:34 The Journey into Systems Biology
10:03 Understanding Digital Twins in Immunology
14:19 The Importance of Personalized Medicine
17:20 Digital Twin Research Funding and Its Impact
18:38 The Role of Digital Twins in Disease Management
21:11 Digital Twin Efforts for Organ Transplants
24:05 Computational C...
2024-12-0232 minBiotalkBiotalk Episode 21: Analyzing the 2024 U.S. Election's Impact on BiotechIn this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, is joined by Andy Meyerson, Managing Director, and Daniel Brog, Senior Vice President, for an insightful discussion on the implications of the 2024 U.S. election results for the biotech industry. The conversation delves into:What Trump's victory could mean for the biotech sector.The potential impact on the HHS and FDA under RFK's leadership.How figures like Elon Musk and Vivek Ramaswamy might influence healthcare policy (DOGE dynamics).We take a balanced approach, covering the potential positive and negative outcomes, imp...
2024-11-2434 minBiotalkBiotalk Episode 20: A Conversation with David Harel of CytoReasonOn this episode of BioTalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market.David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They discuss why no one had applied molecular data this way before, how CytoReason’s models differ from existing approaches, and the benefits they offer in accelerating drug deve...
2024-11-1834 min
BioTalk UnzippedHow AI is Transforming Drug Development: Reflections from AAPS - PharmSci 360 with Dr. Mark ArnoldDr. Mark Arnold, a distinguished bioanalytical thought leader with an impressive track record in supporting drug development programs. Mark is the Owner and Principal at Bioanalytical Solution Integration, where he provides strategic counsel on complex bioanalytical assays and regulatory compliance. With over 35 years of experience, including leadership roles at BMS and Labcorp, Mark has become a key figure in the biotech and pharma industries. He is also an AAPS Fellow and a founder of the Global Bioanalysis Consortium.
01:05 - Career Reflections and Contributions to Drug Development
05:28 - Understanding the Integration of Drug Development
...
2024-11-1836 min
BioTalk UnzippedBiotech Funding Trends and the Rise of Digital Twinning with CEO Scott OgleEP-23. In the second half of this compelling conversation on BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe continue their deep dive with Scott Ogle, CEO of TruLab. They explore the surprising parallels between the banking and pharma industries, the game-changing role of digital twinning in clinical trials, and the biotech funding landscape. Scott also shares his thoughts on leadership, mentorship, and the impact of the Inflation Reduction Act on pharma innovation. This episode offers listeners valuable insights into the future of drug development and the challenges of balancing professional and personal life in a fast-paced industry.
2024-10-2129 minBiotalkBiotalk Episode 19: 2024 Q3 Report: Global Trends in Biopharma TransactionsDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:
Biotech capital markets: The XBI rose 7% in Q3, outperforming the S&P 500, driven by strong clinical readouts and strategic deals, with six IPOs showing strong investor demand.
2024-10-1814 minBiotalkBiotalk Episode 19: 2024 Q3 Report: Global Trends in Biopharma TransactionsDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: The XBI rose 7% in Q3, outperforming the S&P 500, driven by strong clinical readouts and strategic deals, with six I...
2024-10-1814 min
BioTalk UnzippedTechnology Meets Purpose: Transforming Clinical Trials at TruLab with CEO Scott OgleSummary
In this 22nd episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Scott Ogle, CEO of TrueLab, discussing his journey from finance to the pharmaceutical industry, the impact of personal experiences on innovation, and the importance of technology in clinical trials. They explore how to hire the best employees in this climate, the significance of company culture, and the influence of family on business perspectives.
Chapters
00:00 Introduction to BioTalk Unzipped
03:15 The Impact of Personal Experience on Innovation
08:47 TruLab's Technology and Its Role in Clinical T...
2024-10-0233 min
BioTalk UnzippedMentoring in Pharmaceutical Science with Dr. Jim Shen
Mentoring in Pharmaceutical Science with Dr. Jim Shen
Summary
In Episode 21 of BioTalk Unzipped, host Gregory Austin and co-host Dr. Chad Briscoe interview Dr. Jim Shen, the executive director and head of regulated bioanalysis operations at BMS. Jim discusses his early career in bioanalysis and the importance of mentorship. He emphasizes the need to recognize and appreciate the success and expertise of others, as well as the importance of building a network of champions, allies, and sponsors. The conversation also touches on the topic of psychedelics as a drug therapy and the recent retraction of...
2024-09-2935 min
BioTalk UnzippedGreat Advances in Cancer Research with Dr. Jim ShenIn this episode (EP20) of BioTalk Unzipped, host Gregory Austin and co-host Dr. Chad Briscoe interview Dr. Jim Shen, the Executive Director and Head of Regulated Bioanalysis Operations at BMS. They discuss topics such as the advancements in cancer therapies, the integration of AI and mechanistic modeling in drug development, and the complexities of regulatory submissions. Dr. Shen shares his journey into bioanalysis and his passion for mass spectrometry.
Chapters
01:15 - Introduction, Background, and Passion for The American Cancer Society
03:46 - Advancements in Cancer Therapies, Opdualag
08:03 - From Small Molecule to La...
2024-09-0137 minBiotalkBiotalk Episode 18: A Conversation with Lindsay Rosenwald of Fortress BiotechOn this episode of Biotalk, Locust Walk’s Andy Meyerson welcomes Dr. Lindsay Rosenwald, Chairman, President and Chief Executive Officer of Fortress Biotech, a company focused on licensing and developing high-potential marketed and development-stage drugs.
Lindsay shares his journey from physician to biotech entrepreneur and outlines Fortress Biotech’s strategy of licensing high-potential marketed and development-stage drug candidates, avoiding early-stage technologies. They discuss how Fortress capitalizes on inefficiencies in the drug development market, such as acquiring drugs approved abroad but not in the US, and the role of AI in improving drug search and evaluation efficiency.
Despit...
2024-08-1626 min
BioTalk UnzippedThe Future of Hybrid Healthcare: Insights from Zealic CEO Chuck PiccirilloIn this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe continue their conversation with Zealic CEO, Chuck Piccirillo. They delve into the unique challenges of the patient journey and the increasing demand for hybrid healthcare solutions that offer more flexibility. The discussion highlights the rise of virtual health, particularly in Europe, and introduces exciting developments in ion channels as a goldmine for new medicines. They also explore the financial intricacies of drug development, the importance of leadership through incremental steps, the value of in-person interactions, and hard-earned lessons in the industry. Finally, Chuck offers invaluable advice for...
2024-08-1539 min
BioTalk with Rich BendisExploring ARPA-H Innovations: Insights with Craig Gravitz and Jenica Patterson, Ph.D.In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes guests from ARPA-H: Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO), and Jenica Patterson, Ph.D., Portfolio Lead at ARPA-H. Together, they provide a comprehensive overview of ARPA-H's mission and innovative programs. Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.
2024-08-0539 min
BioTalk UnzippedGenetic Diagnostics & Student CEOs with Dr. Jonathon HillSummary
In this conversation, Dr. Jonathon Hill discusses the unique partnership between his lab and the university, which allows students to become entrepreneurs, develop their own projects, and become the CEO. Dr. Hill discusses the potential for AI to better diagnose disease based on the individual’s genome. He also talks about Lumicell's fluorescent system for highlighting residual breast cancer tissue and the importance of genetic diagnostics in personalized medicine. Dr. Hill shares his advice for students interested in genetics and biotechnology research, emphasizing the value of research experience and taking risks. He also discusses the challenges of...
2024-08-0433 min
BioTalk UnzippedHow AI is Helping Diagnose Disease with Chuck PiccirilloSummary
In this conversation, Gregory Austin and Chad Briscoe interview Chuck Piccirillo, CEO of Zealic Health, about his experience in the healthcare industry and the focus on patient-centric solutions. Chuck shares his personal journey with colitis and how it ultimately inspired him to start Zealic Health. The company aims to provide highly patient-centric digital platforms to improve care and treatment in the healthcare industry. Chuck also shares the story of how Zealic Health adapted to the war in Ukraine and relocated their employees to Poland.
The panel tackles the tough questions around the new LDT as a...
2024-08-0238 min
BioTalk with Rich BendisBioHealth Capital Region Maintains #3 Ranking: Insights with GEN's Alex PhilippidisIn this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. Alex joins the podcast to discuss the latest Top 10 U.S. Biopharma Clusters list, where the BioHealth Capital Region secured its #3 ranking for the second consecutive year. The conversation highlights the factors that contributed to the success of the top biopharma clusters, focusing on early investments in biotech, the generation of high-quality science, building networks with partners, and broadening clusters beyond anchor businesses. Alex elaborates on how these regions h...
2024-07-2836 min
BioTalk with Rich BendisLife Sciences Real Estate and Talent Trends: Insights from Matt Gardner, Head of Life Sciences, Americas, CBREIn this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Matt Gardner, Head of Life Sciences, Americas, at CBRE. With over 30 years of experience in the technology and life sciences sectors, Matt Gardner provides a comprehensive look at the latest trends and developments in the life sciences industry. Matt shares key findings from CBRE's recently released 'U.S. Life Sciences Talent Trends' report for 2024 (https://www.cbre.com/insights/books/us-life-sciences-talent-trends-2024), offering insights into what the life sciences sector can expect in the coming year. He discusses the national r...
2024-07-2140 minBiotalkBiotalk Episode 17: Q2 2024 Report: Global Trends in Biopharma TransactionsDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:
Biotech capital markets: The XBI remained flat in Q2, diverging from the bullish S&P 500, with fewer IPOs but more capital for later-stage companies.
Privat...
2024-07-1912 minBiotalkBiotalk Episode 17: Q2 2024 Report: Global Trends in Biopharma Transactions/*! elementor - v3.23.0 - 25-07-2024 */
.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}
CATEGORIES
News
Events
Publications
ARCHIVE
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2024-07-1912 min
BioTalk UnzippedReptiles, Treatments, and Cell-Gene Therapy with Dr. VickSummary
Dr. Andy Vick shares some of the things that surprised him throughout his career and he discusses his passion for reptiles and his experience discussing the pharmaceutical potential of venom with future toxicologists at Ashland University. Next, Andrew Vick discusses his role as an adjunct professor at Ohio State University, his involvement in academia, and how he got into it. We discuss a story about a clinical study that restored hearing in children with gene therapy. The conversation concludes with a discussion about the impact of professional organizations like AAPS on the industry and the importance...
2024-07-1538 min
BioTalk with Rich BendisStrengthening Ties: U.S.-Tunisia Cooperation in Science and Technology with Ambassador Joey R. HoodIn this episode of BioTalk with Rich Bendis, we have the honor of speaking with the U.S. Ambassador to the Republic of Tunisia, Joey R. Hood. With an impressive diplomacy and international relations background, Ambassador Hood sheds light on the vital collaboration between the U.S. and Tunisia in scientific research, innovation, and technology transfer. Host Rich Bendis is the President and CEO of BioHealth Innovation, Inc., dedicated to accelerating biohealth opportunities and fostering innovation across the BioHealth Capital Region of Maryland, Washington D.C., and Virginia….and the world. Ambassador Hood discusses the cur...
2024-07-1437 min
BioTalk UnzippedAmyloidosis Exposed: New Hope with Dr. VickSummary
Dr. Andy Vick discusses his work at Attralus Therapeutics, a biotech company focused on developing treatments for systemic amyloidosis. He explains the etiology of the disease and how Attralus is attacking it using therapeutic antibodies with a pan amyloid reactive peptide sequence. The company is also developing a diagnostic tool to visualize amyloid burden in patients. Dr. Vick emphasizes the importance of toxicology in drug discovery and development, describing its role in evaluating the adverse side effects of drugs and ensuring safety. He also highlights the challenges of finding animal models for rare diseases like amyloidosis...
2024-07-0140 min
BioTalk with Rich BendisShaping the Future of Health Computing in the BioHealth Capital Region: Insights from Dr. Bradley MaronJoin us for an episode of BioTalk with Rich Bendis featuring Dr. Bradley Maron, Senior Associate Dean for Precision Medicine and Executive Co-Director of the University of Maryland-Institute for Health Computing at the University of Maryland School of Medicine. With his extensive background in cardiovascular research and precision medicine, Dr. Maron offers a wealth of knowledge and innovative perspectives. In this episode, Dr. Maron shares his professional journey, discussing his various roles at the University of Maryland and what drew him to the region. He provides a comparative analysis of the ecosystems in Boston/Harvard a...
2024-06-3041 min
BioTalk with Rich BendisLeading the Charge in Tech-Based Economic Development: A Conversation with Dan Berglund of SSTIJoin us for an enlightening episode of BioTalk with Rich Bendis as we welcome Dan Berglund, President and CEO of SSTI. With nearly four decades of experience in tech-based economic development (TBED), Dan has been a pivotal figure in shaping the landscape of innovation and entrepreneurship across the nation. In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have d...
2024-06-1643 min
BioTalk UnzippedA Diagnostic Breakthrough for Alzheimer’s with Dr. Jonathon HillA Diagnostic Breakthrough for Alzheimer’s
Summary
In this conversation, Dr. Jonathan Hill discusses his work in nanopore sequencing-based technology and its applications in genetic and epigenetic research. He shares his experiences working in Brazil and his passion for preserving the rainforest. The conversation also explores the use of AI in analyzing the genetic underpinnings of tobacco addiction and the potential impact on addiction treatment. Dr. Hill highlights his lab's breakthrough in identifying early biomarkers for Alzheimer's disease using DNA methylation signatures.
Takeaways
Nanopore sequencing is a powerful technology that allows for...
2024-06-0130 minBiotalkBiotalk Episode 16: A Conversation with Stephen Sands of LazardOn this episode of Biotalk, Locust Walk’s Geoff Meyerson welcomes Stephen Sands, former Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group, and currently Senior Advisor at Lazard, a renowned name in global financial services. Together, they explore Stephen’s journey into life sciences finance, his transition into financial and management roles within healthcare, his mentors, and how these relationships impacted his career.
Geoff and Stephen also tackle the evolution of banking in today’s healthcare investment landscape, highlighting specialization’s role. They cover navigating challenges and strategies in investments, including banking structures, capital mark...
2024-05-1533 min
BioTalk UnzippedThe AI Prescription: Revolutionizing Pharma & Patient Care with Jason BurkeThe AI Prescription: Revolutionizing Pharma & Patient Care with Jason Burke
Summary
In Episode 13, Jason Burke discusses the unique approach of the Duke program in providing real-world healthcare data to students. He also highlights the breakthrough in AI-generated drug discovery and its potential impact on investors and startups. The process of assessing technologies for companies and patients is explored, with a focus on evaluating business and technology aspects. The importance of unique intellectual property is emphasized, and the future of AI and software is discussed. The conversation concludes with insights into using AI in everyday life...
2024-05-1535 minBiotalkBiotalk Episode 16: A Conversation with Stephen Sands of Lazard/*! elementor - v3.21.0 - 26-05-2024 */
.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}
CATEGORIES
News
Events
Publications
ARCHIVE
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2024-05-1500 min
BioTalk UnzippedUnlocking the Future of Healthcare with Organoids, AI, and Quantum Computing with Jason BurkeSummary
In this episode of BioTalk Unzipped, the hosts discuss the applications and ethical concerns surrounding organoids, which are 3D cell clusters that mimic the features of full-sized organs. They explore the potential of brain organoids in brain-computer interfaces and neuroplasticity. The conversation then shifts to the impact of AI and data sciences in healthcare, with a focus on the challenges and opportunities in implementing AI strategies. The hosts also discuss the future of quantum computing in healthcare and the FDA's IT strategy with 21 CFR Part 11.
Chapters
01:14 - Introduction to BioTalk Unzipped
2024-05-0134 min
BioTalk UnzippedHow To Prevent And Fix PAINFUL Medical Device Recalls with Debbie ChurchPodcast Show Notes:
“How To Prevent And Fix PAINFUL Medical Device Recalls with Debbie Church”
Host: Gregory Austin
Guest: Debbie Church, Regulatory
Senior Manager, Enhanced Compliance Inc. (ECI)
In this Bonus Episode (EP11) you get to watch a recording from a previous LinkedIn Live show discussing the methods, strategies, and techniques you can use to prevent and remediate Medical Device
Recalls.
Introduction
Gregory Austin, Business Development Lead for Enhanced Compliance Inc. (ECI), welcomes listeners to the BioTalk Unzipped podcast’s LinkedIn Live session.
Special guest: Debbie Church, Regulatory Senior Manager at ECI, with ove...
2024-04-2223 minBiotalkBiotalk Episode 15: 2024 Q1 Report: Global Trends in Biopharma TransactionsDuring this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:
Biotech capital markets: Highlighting XBI’s recovery, strong market indicators, and increased PIPE activity since Q2 2023.
Private biotech markets: Saw the second-best deal quarter since 2021, yet activity remains flat com...
2024-04-1611 minBiotalkBiotalk Episode 15: 2024 Q1 Report: Global Trends in Biopharma Transactions/*! elementor - v3.21.0 - 26-05-2024 */
.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}
CATEGORIES
News
Events
Publications
CATEGORIES
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2024-04-1600 min
BioTalk UnzippedBreakthrough in Melanoma, Rare Diseases, and Curative Therapies with Scott SchliebnerSummary
In this episode, Scott Schliebner discusses the unique challenges and complexities of rare disease trials. He highlights the difficulties in recruiting patients, the multidisciplinary nature of care, and the importance of collaboration among various stakeholders. The role of AI in rare disease trials is also explored, with a focus on its potential for patient recruitment and data analysis.
Scott shares success stories in the field and discusses the expanding use of gene therapy to target multiple genes. The conversation concludes with a discussion on the recent FDA approval of Iovance's Amtogvy as the first T...
2024-04-1636 min
BioTalk UnzippedImpact of AI in Rare Disease Trials with Scott SchliebnerImpact of AI in Rare Disease Trials with Scott Schliebner
Summary
In this episode, the hosts welcome Scott Schliebner as their guest and kick off with a charitable act, donating to Rare Givers. They delve into the Epitomee weight loss capsule's potential impact, then shift to discussing the challenges of establishing a North American infrastructure for a MedTech CRO, navigating cross-cultural dynamics. Later, they investigate the transformative potential of AI and machine learning in clinical trials. Scott Schliebner weighs in on the intricacies of rare disease trials, emphasizing patient recruitment hurdles, interdisciplinary care, and...
2024-04-0136 min
BioTalk UnzippedInvaluable Lessons in Leadership and Science with Dr. Russell GrantDescription:
In Episode 8 of BioTalk Unzipped, we dive deep into the scientific mind of Dr. Russell Grant, exploring how he navigates groundbreaking publications with a healthy dose of skepticism. From microsampling blood spots to dissecting experimental execution gaps, Dr. Grant reveals his strategies for separating scientific sizzle from substance.
In our latest segment of "New News," we discuss Elon Musk's Neurolink gaining FDA approval for clinical trials, sparking debates about neuroscience's role in the 21st century. With insights into the risks and rewards of understanding brain biochemistry, this episode challenges conventional thinking.
Discover...
2024-03-1543 min
BioTalk UnzippedRevolutionizing Diagnostic Patient Care with Dr. Russell GrantJoin us for Episode 7 of our podcast as we delve into the fascinating journey of Dr. Russell Grant, from the UK to America, navigating through large pharma to the field of diagnostics. Discover the nuances between bioanalytical approaches in clinical trials versus clinical healthcare, and Russ's insights on GLP environments. Learn how Russ tackled the challenges of COVID, and hear the incredible New News breakthrough in restoring hearing in an 11-year-old using gene therapy. Russ shares his American dream, his passion for diagnostics, and his thoughts on scientific integrity. Tune in for a captivating discussion on the critical role...
2024-03-0133 min
BioTalk with Rich BendisEmpowering Change: Lance Kawaguchi's Journey with the Cure Brain Cancer FoundationJoin us for an engaging episode of BioTalk as we sit down with Lance Kawaguchi, Chief Executive Officer of the Cure Brain Cancer Foundation. Lance's career trajectory from global finance to non-profit leadership is as inspiring as it is impactful, driven by a personal mission to combat brain cancer following the loss of his mother. In this episode, we explore Lance's journey from senior investment banker to non-profit leader, propelled by personal loss and a vision for change. We delve into the SouthPoleTrek4Cancer initiative, spearheading a global effort to raise awareness and funds for b...
2024-02-2527 min
BioTalk UnzippedFalse Positives In The AI Explosion with Dr. Stephanie Pasas FarmerWelcome to Episode 6 of our podcast featuring Dr. Stephanie Pasas Farmer! 🎙️ Join us as we delve into the intricate world of data integrity, unveiling new software tools and the transformative impact they bring. Discover how virtual audits post-COVID, coupled with cloud security measures, are reshaping the landscape. 🔍
Explore the regulatory challenges amidst the technology and the AI explosion, with insights into the FDA's evolving role and its mission for public safety. Learn how ChatGPT transcends boundaries, from revolutionizing travel planning to enhancing workplace productivity. 💼
Delve into the nuances of ChatGPT's capabilities and limitations, navigating the fine line b...
2024-02-1533 min
BioTalk UnzippedHow To Start A Company In Bioanalysis with Dr. Stephanie Pasas Farmer🎙️ Episode 5 of BioTalk Unzipped is here! Join hosts Gregory Austin and Dr. Chad Briscoe as they chat with Dr. Stephanie Pasas Farmer, founder of Ariadne Software and BioData Solutions. Explore the origins of Stephanie's companies, and the creation of RedThread, an AI-Enabled Auditing Tool that blends human intelligence with AI.
🧠 Dive into the practical side of Stephanie's software and the ever-evolving landscape of machine learning regulations. Get a glimpse into Stephanie's perspective on machine learning vs. expert systems and the challenges of navigating this dynamic field.
🌐 Discover what lies ahead for AI in Stephanie's software and the int...
2024-02-0127 minBiotalkBiotalk Episode 13: 2023 Year-In-Review Report: Global Trends in Biopharma TransactionsIn this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:
Biotech capital markets: XBI performance and IPO volume
Private biotech markets: Financing deal value and volume remained flat
Strategic transaction activity: Q4 marked a surge in multi-billion-dollar acquisitions
Market outlook and advice for the year ahead
We invite you to listen to our podcast and download our report for the Insights page and welcome the opportunity to discuss its contents with you.
Timestamps:
Deal Context: 0:37
Our Advice for the Current Market: 6:11
Transcription:
Welc...
2024-01-2411 min
BioTalk UnzippedSickle Cell Breakthrough and Heartbreaking Stories with Dr. Russ WeinerIn Episode 4, (Part 2 of our conversation with Dr. Russ Weiner - a top scientific leader at Takeda), we boldly explore the Cell and Gene Therapy Industry, questioning its trajectory and potential impact on insurance companies.
Shifting focus, we delve into a groundbreaking Sickle Cell Therapy breakthrough, discussing its triumphs, challenges, and the crucial aspect of affordability. Despite the hurdles faced by payers and insurance companies, we find inspiration in the thrill of witnessing healing.
Discover the role of AAPS in shaping the biotech future and efforts to engage students. Episode 4 also highlights Russ’ passions, including a...
2024-01-1535 min
BioTalk UnzippedMiraculous Cures: From Hospice to Survivor with Dr. Russ WeinerIn Episode 3 of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe dive deep into the world of biotech with an exclusive interview featuring the esteemed Dr. Russ Weiner. As a senior-level biopharmaceutical professional with over 30 years of hands-on experience, Dr. Weiner shares invaluable insights into pharmaceutical and biologic drug discovery/development, clinical trial conduct, and project leadership.
The episode unfolds with a detailed exploration of Dr. Weiner's impressive career, starting with his journey into the industry and an incredible success story in hospice care. The conversation transitions into the dynamic changes witnessed in the past three decades, particularly...
2024-01-0236 min
BioTalk UnzippedScience is NOT a Conspiracy Theory with Dr. Chad Briscoe & Gregory AustinWelcome to another engaging episode of "BioTalk Unzipped" – the podcast where we unravel the fascinating world of biotechnology and drug discovery and unzip the stories behind medical progress. In Episode 2, we delve into the heart of the matter, exploring the new and painful challenges faced in the realm of drug discovery and development, as well as examining the public's perception of this critical science. Gregory makes a declarative statement about science.
Join our insightful co-host, Chad Briscoe, as he and Gregory discuss the exciting possibilities surrounding the use of AI in drug discovery and development. Discover how cut...
2023-12-1526 minBiotalkBiotalk Episode 12: A Conversation with Soufiane Aboulhouda of NucleateOn this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Soufiane Aboulhouda, Co-Founder and Chairman of the Board of Nucleate, a global non-profit dedicated to empowering future biotech leaders through education and fostering innovation in life sciences companies. The discussion explores Soufiane’s journey into early-stage biotech and delves into the founding story of Nucleate, highlighting the organization’s mission and its pivotal role in shaping the biotech landscape.
Soufiane, who served as President of Nucleate for over 5 years, shares valuable lessons learned during his tenure. Listeners also gain insights into Soufiane’s current work at the Wyss Inst...
2023-12-0432 minBiotalkBiotalk Episode 12: A Conversation with Soufiane Aboulhouda of Nucleate/*! elementor - v3.21.0 - 08-05-2024 */
.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}
Biotalk Episode 12: A Conversation with Soufiane Aboulhouda of Nucleate
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes with Soufiane Aboulhouda, Co-Founder and Chairman of the Board of Nucleate, a global non-profit dedicated to empowering future biotech leaders through education and fostering innovati...
2023-12-0400 min
BioTalk UnzippedCheers to Science: The BioTalk Unzipped Vision (Trailer)Dr. Chad Briscoe Unveils the Vision - When Bar Conversations Meet Scientific Breakthroughs. Bringing great pharmaceutical science to the people in a light, fun, and inspirational manner.
#biotechnology
#pharmaceutical
#science
#drugdevelopment
#drugdiscovery
#research
2023-11-2800 min
BioTalk UnzippedThe BioTalk Unzipped Premiere: Why Biotech Companies FailWelcome to the premiere of BioTalk Unzipped, the podcast where the complex world of biotechnology gets unzipped by your hosts, Gregory Austin and Dr. Chad Briscoe. In this inaugural episode, we invite you to pull up a virtual chair and join us in an enlightening conversation that transcends the boundaries of traditional scientific discussions.
What's on the Table?
Discover the pulse of the biotech industry as we dive into the latest headlines and unravel the stories shaping the future. Gregory and Dr. Chad bring their unique perspectives to the table, shedding light on the trends...
2023-11-2725 minBiotalkBiotalk Episode 11: A Conversation with Shehnaaz Suliman of ReCode TherapeuticsOn this episode of Biotalk, Locust Walk‘s Daniel Brog welcomes with Shehnaaz Suliman, M.D., CEO of ReCode Therapeutics, a clinical-stage genetic medicines company using its selective organ targeting lipid nanoparticle platform to power the next wave of mRNA and gene correction therapeutics.
With over 25 years of experience, Shehnaaz brings a multifaceted perspective to the discussion. She has held diverse roles, from practicing physician to dealmaker, and now leads the charge at ReCode. Join us as we delve into the distinctive qualities that set ReCode apart and to discover the groundbreaking technology behind their selective organ targeti...
2023-11-141h 00BiotalkBiotalk Episode 11: A Conversation with Shehnaaz Suliman of ReCode Therapeutics/*! elementor - v3.21.0 - 08-05-2024 */
.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}
Biotalk Episode 11: A Conversation with Shehnaaz Suliman of ReCode Therapeutics
Click Here for a full summary of the episode. On this episode of Biotalk, Locust Walk‘s Daniel Brog welcomes with Shehnaaz Suliman, M.D., CEO of ReCode Therapeutics, a clinical-stage genetic medicines company using its selective organ targeting lipid nanoparticle platform to power th...
2023-11-1400 minBiotalkBiotalk Episode 10: A Conversation with Errik Anderson of Alloy TherapeuticsOn this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Errik Anderson, CEO and Founder of Alloy Therapeutics, to the podcast. Alloy is a trailblazing drug-discovery company, bringing collaborative platforms and services to the biotech world, making cutting-edge biologics accessible to everyone, from academia and small biotechs to major pharmaceutical companies.
Errik, with a unique blend of entrepreneurship, venture capital, and a passion for rugby, shares his journey from Adimab to founding Alloy, highlighting Alloy’s distinctiveness in biotech. He also discusses Alloy’s future plans and their excitement about the anticlastic ASO technology.
During the...
2023-10-3054 min
BioTalk with Rich BendisRevolutionizing Autoimmune Medicine: MyMD Pharmaceuticals Innovative TherapiesAre you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations i...
2023-10-1541 min
BioTalk with Rich BendisBioTalk Discusses Breaking Frontiers in Immunotherapy: A Conversation with Bill Enright, CEO and Board Director at VaccitechWhat does it take to pioneer groundbreaking T-cell immunotherapies and vaccines for infectious diseases and cancer? Join us for this episode of BioTalk, where we sit down with Bill Enright, a seasoned biotech executive with a remarkable track record spanning over three decades. Bill brings a wealth of experience in building and financing both privately held and publicly traded companies, making his mark in various roles within the life science/biotech industry. Bill offers a compelling update in this installment since his previous appearance on BioTalk. Learn about the intriguing journey that led Vaccitech, a clinical-stage T...
2023-08-2028 min
BioTalk with Rich BendisNavigating Growth and Collaboration in Life Sciences: A Conversation with Brad L. Stewart, SVP of Business Development, MCEDCHow does a region evolve to become a leading driver in the BioHealth Capital Region? What are the secrets behind the successful collaboration between various organizations like MCEDC (Montgomery County Economic Development Corporation), MTC (Maryland Tech Council), and the Maryland Department of Commerce? How does a serial biotech entrepreneur leverage his experience to grow a diverse cross-section of businesses, including life sciences, technology, cybersecurity, defense, and hospitality? In this episode of BioTalk, host Rich Bendis chats with Brad L. Stewart, SVP of Economic Development for Montgomery County Economic Development Corporation (MCEDC). Brad's multifaceted career spans from being...
2023-08-0736 min
BioTalk with Rich BendisBuilding Better Medicine, and Transformative Partnerships: Insights from Joy Polefrone, Ph.D. on BioTalkEver wondered how public-private partnerships can make a significant difference in the field of life sciences? Curious about the goals, expected impacts, and timeline of the Alliance for Building Better Medicine (ABBM)? Interested in exploring the transformative potential of the Virginia BioHealth ecosystem and its role in advancing the life sciences industry? In this episode of BioTalk, join host Rich Bendis as he interviews Joy Polefrone, Ph.D., Executive Director of the Alliance for Building Better Medicine (ABBM). Joy brings two decades of diverse business leadership and organizational strategy experience. They discuss career shifts in academia, industry...
2023-07-0938 min
BioTalk with Rich BendisUnveiling the Life Sciences Landscape: Insights from CBRE Experts on BioTalk with Rich BendisAre you curious to discover how experts navigate the complex landscape of life sciences real estate? Want to stay ahead of the curve in the market today? Ready to learn about the latest talent dynamics in the field? Join Rich Bendis on BioTalk as he discusses the world of life sciences real estate and market trends with CBRE's experts, Dan Grimes, Senior VP at CBRE's Mid-Atlantic Life Sciences practice, and Ian Anderson, Senior Director of Research and Analysis. Together, they discuss the 2023 "US Life Sciences Research Talent Report" and the BioHealth Capital Region's Top 3 ranking. ...
2023-06-2544 minBioTalk with Rich BendisFrom Vision to Action: MEDCO's Role in Economic Development and Partnerships on BioTalk with Rich BendisIn this captivating episode of BioTalk, Rich Bendis sits down with Tom Sadowski, the Executive Director of the Maryland Economic Development Corporation (MEDCO). With over 30 years of experience in economic development, Tom has played a pivotal role in translating vision into action. Together we explore MEDCO's significant contributions to economic development and their strategic partnerships across Maryland. Tom shares his remarkable career accomplishments, including successful projects valued at over $10 billion and the creation of 50,000 jobs. His expertise in fostering research partnerships, technology commercialization, and his role in launching the Maryland Momentum Fund bring invaluable insights to the...
2023-06-1831 minBioTalk with Rich BendisFrom Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of Ampel BioSolutions, Joins BioTalkCan you envision a world where precision medicine transforms healthcare as we know it? Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of Ampel BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind Ampel's remarkable success in precision medicine, making this episode a must-listen. Learn about the groundbreaking genomic tests developed by Ampel, providing decision support for autoimmune diseases, and delve into the role of artificial intelligence in predicting potential treatments. Explore the immense potential for a revolution in healthcare as Dr. Grammer shares insights on understanding...
2023-05-2143 minBioTalk with Rich BendisNavigating the Challenges of Rare Disease Research with Dr. Harsha Rajasimha on BioTalkJoin us for an enlightening episode of BioTalk with Rich Bendis as we explore the pivotal role of patient registries in rare disease research and treatment. Our guest, Harsha Rajasimha, MS, Ph.D., CEO of Jeeva Informatics Solutions and Founder and Executive Chairman of IndoUSrare, shares his extensive experience in clinical genomics data science and precision medicine. In this episode, Dr. Rajasimha introduces Jeeva Informatics Solutions and IndoUSrare, his non-profit organization. He discusses the importance of patient registries in accelerating rare disease research, the current obstacles in the field, and the potential solutions. We discuss...
2023-05-1340 minBioTalk with Rich BendisDr. Leroy Hood and Dr. Nathan Price, Co-Authors of "The Age of Scientific WellnessWhat if the future of medicine could be personalized, predictive, and empowered by data? In this episode of BioTalk, Rich Bendis discusses this topic with Dr. Leroy Hood and Dr. Nathan Price, the co-authors of the book "The Age of Scientific Wellness: Why the Future of Medicine Is Personalized, Predictive, Data-Rich, and in Your Hands." Together, they discuss the scientific revolution reshaping the healthcare and medicine landscape. Dr. Hood and Dr. Price shed light on how cutting-edge technologies, such as genomics and artificial intelligence, are enabling the shift from reactive medicine to proactive, individualized care. They explore...
2023-04-0659 min
BioTalkSeason 2 Ep. 6: Menjadi Mahasiswa Berprestasi Versi Anak BiologiHalo sobat Biota!!! Gimana sii caranya ikut banyak kompetisi di tengah sibuknya perkuliahan? Di episode kali ini, kita akan membahas seputar tips and trick mengikuti kompetisi ilmiah. Let's take comfortable position and enjoy it!
2023-01-1823 min
BioTalkSeason 2 ep. 5 (Part 2): Serba-Serbi KKNHollaaa Sobat Biota!!! Setelah dengerin part 1 Serba-Serbi KKN pasti pada makin kepo kan mengenai kegiatan KKN? Yukk langsung ajaa dengerin part 2 yang pastinya makin seru! Let's take comfortable position and enjoy it!
2022-10-3129 min
BioTalkSeason 2 ep. 5 (Part 1): Serba-Serbi KKNHai hai haii Sobat Biota!!! Kira-kira KKN tuh ngapain aja sih? Pastii pada penasaran kan, apalagi yang belum KKN nih. Di episode kali ini, kita akan bahas seputar KKN bersama mas Riyo Bio'19. Let's take comfortable position and enjoy it!
2022-10-3132 min
BioTalkSeason 2 Ep. 4: Pelonggaran Aturan Penggunaan Masker, Sudah Mungkin kah Kita Melepas Masker?Ada yang baru nih di Episode BioTalk!! Kali ini, kita berkolaborasi dengan Dinding Opini Himbio Departemen Kastrat! Let's take comfortable position and enjoy it!
2022-08-3109 min
BioTalkSeason 2 Ep. 3: Prepare for Offline Final ExamHaloooo sobat Biota! Setelah menjalankan 1 semester perkuliahan, kita harus menjalankan ujian akhir. Ujian akhir kali ini pertama kali kita laksanain secara offline setelah beberapa semester kemarin online. Pastinyaa banyak banget nih yang harus disiapin. Biar makin siap dalam menghadapi ujian akhir, bisa banget dengerin beberapa tips dari kami! Let's take comfortable position and enjoy it!
2022-06-2604 min
BioTalkSeason 2 Ep 2: Mengulik Lebih Dalam tentang Kepenulisan dan Antologi CerpenHaii haii haiii sobat Biota! Kali ini kita kedatangan narasumber hebat di bidang kepenulisan. Di episode kali ini kitaaa akan sharing-sharing mengenai kepenulisan khususnya antologi cerpen bersama Indah dari Bio'20. Let's take comfortable position and enjoy it!
2022-05-3123 min
BioTalkSeason 2 Ep. 1: How to Get Almost Perfect gpaHalooo sobat Biota! Pasti pada penasaran kan gimana caranya dapet ipk tinggi tapi masih bisa aktif organisasi. Di episode kali ini, kita akan membahas mengenai tips&trick dunia perkuliahan bersama Mbak Melly Bio'18. Let's take comfortable position and enjoy it!
2022-04-2828 min
BioTalkSeason 2 Ep. 0: Let's BeginSetiap akhir sebuah cerita, akan selalu menciptakan awal cerita baru. Haloo sobat Biota! Yang dinantikan akhirnya datang kembali. Let's take comfortable position and enjoy it!
2022-03-2701 min
2021-09-2305 min
BioTalkObrolan Santai Edisi Kemerdekaan [Part 2]Halo himbionist! Di episode kali ini, kita kedatangan guest star yang kece banget nih, yaitu Icha dari Bee's 19, Diyah dari Bee's 19, dan Iyon dari Bee's 20 untuk ngobrol-ngobrol bareng seputar hari kemerdekaan Indonesia. Yuk, kita dengar cerita-cerita tentang 17 agustus-an dari mereka!
2021-09-2320 min
BioTalkObrolan Santai Edisi Kemerdekaan [Part 1]Halo himbionist! Di episode kali ini, kita kedatangan guest star yang kece banget nih, yaitu Inez dari Bee's 19 dan Rama dari Bee's 20 untuk ngobrol-ngobrol bareng seputar hari kemerdekaan Indonesia. Yuk, kita dengar cerita-cerita tentang 17 agustus-an dari mereka!
2021-09-2315 min
BioTalkThe Selfish Gene -Richard DawkinsKita adalah mesin reproduksi seksual, meloncat dari generasi ke generasi untuk bertahan hidup. Diperlukan adanya kompetisi untuk mencapai tujuan masing-masing, tetapi dalam mencapai suatu misi perlu adanya kerja sama untuk menciptakan produk terbaik yang berhasil menjadi penyintas dari masa lampau.
2021-06-2717 min
BioTalkKabinet Akusara Menyapa!Halo Himbio, Unair dan Indonesia! Segala sesuatu akan berubah seiring berjalannya waktu. Termasuk juga dirimu, sebagai manusia yang akan terus berkembang dan menua. Perubahan ini juga terjadi pada tampilan yang akan terus menyesuaikan perkembangan zaman. Kini kabinet akusara Himbio Unair 2021 hadir lebih dekat sedekat telinga dengan earphone-mu melalui kanal podcast ini juga sebagai pengawal yang terus mengalami perkembangan dan perubahan dalam setiap tampilannya. Jadi for the first time kabinet akusara kali ini menggunakan media podcast yang diberi nama “BIOTALK”. So, biar ga penasaran lagi, langsung aja dengerin podcast dari kami. See you on the next podcast!
2021-05-0902 min
CausepodsThe More We Know with Rich Bendis of the BioTalk PodcastWho do you know that others need to know?We are always one conversation away from changing our lives, and Rich Bendis of BioHealth Innovations started the BioTalk podcast to connect the world of bio-health better. In a world where medical science advances are growing at the fastest pace in human history, we can still run into a problem where the people who know each other don’t get connected to advance therapy, new medicine, or new approaches. Key Topics:What is the goal of Biohealth Innovations (1:44)How has the medical research chan...
2021-03-2221 min
BioTalkBioTalk16: Genetic Enhancements, A “Biological Arms Race” That No One Can WinLast year the UK became the first in the world to offer controversial ‘three-parent’ fertility treatments. This year they approved the use of CRISPR to edit genomes of human embryos. In the latest episode of BioTalk, we discuss how scientists and governments have re-engineered language to sell the public on embryo-re-engineering (http://www.ncregister.com/daily-news/scientists-governments-re-engineer-language-to-sell-public-on-embryo-re-eng/). We also look at the long-term implications of genetic enhancement. Specifically, how enhancement leads to coercion and the loss of human dignity (http://www.catholiclane.com/the-seductive-siren-song-of-genetic-enhancement/).
2016-05-0632 min
BioTalkBioTalk Episode 2: Three Parent Embryos and the Brave New United StatesIn October of last year, scientists in Oregon made embryos with genes from one man and two women: http://lacrossetribune.com/oregon-scientists-make--parent-embryos/article_d4035b9a-1e62-11e2-8218-0019bb2963f4.html
Rebecca and Chelsea discuss this kind of genetic engineering and the "Brave New" United States where there are no restrictions on this or other once unthinkable kinds of human experimentation currently in practice. We also discuss the impact this kind of experimentation has on women.
2016-01-2924 min
BioTalkBioTalk, Episode 1: Prenatal Genetic TestingWhile genetic testing isn't bad, in and of itself, it can be used unethically.
2016-01-2822 min